Viridian Therapeutics, Inc. (VRDN): Revenue
$70.85M
Year ended 2025-12-31
$71.13M
Trailing 12 months to 2026-06-30
+241.9%
3-year compound annual growth
n/m
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $70.85M | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $302.0K | -3.8% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $314.0K | -82.3% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $1.77M | -40.2% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $2.96M | +182.2% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $1.05M | -76.5% | 2022-03-11, From 2020-01-01 |
| 2019-12-31 | $4.46M | -46.8% | 2021-03-26, From 2019-01-01 |
| 2018-12-31 | $8.39M | +109.5% | 2020-03-13, From 2018-01-01 |
| 2017-12-31 | $4.00M | +15.1% | 2019-03-14, From 2017-01-01 |
| 2016-12-31 | $3.48M | n/c | 2018-03-15, From 2016-01-01 |
| 2015-12-31 | $2.54M | -41.3% | 2017-03-24, From 2015-01-01 |
| 2014-12-31 | $4.32M | +0.1% | 2016-03-21, From 2014-01-01 |
| 2013-12-31 | $4.32M | n/a | 2015-03-27, From 2013-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $70.85M | n/m |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $72.30M | +153.5% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $69.26M | -31.8% |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $72.59M | +105.8% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $67.48M | +25.2% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $75.13M | +160.6% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $66.80M | +39.2% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $76.20M | -44.8% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $65.32M | -3.4% |
Compare VRDN, ASMB, RMTI, BCYC side by side · Screen every company in Pharmaceutical Preparations ↗